Stockreport

Arvinas Presents a Platform Update, Including Initial Data from the First Two Clinical Trials of PROTAC® Targeted Protein Degraders

Arvinas, Inc.  (ARVN) 
Last arvinas, inc. earnings: 11/4 05:00 pm Check Earnings Report
PDF -Data from initial cohorts suggest that Arvinas’ PROTAC® platform has the potential to create safe and well-tolerated orally bioavailable drugs for the treatment of cert [Read more]